Publications by authors named "H Weidner"
Establishing a strategy for sequencing of T cell-redirecting therapies for relapsed/refractory multiple myeloma (RRMM) is a pressing clinical need. We longitudinally tracked the clinical and immunologic impact of bispecific T cell-engaging antibodies (BsAb) as bridging therapy (BT) to subsequent B-cell maturation antigen-directed chimeric antigen receptor T (CAR-T) cell therapies in 52 patients with RRMM. BsAbs were a potent and safe option for BT, achieving the highest overall response rate (100%) to BT compared with chemotherapy, anti-CD38, or anti-SLAMF7 antibody-based regimens (46%).
View Article and Find Full Text PDFArticle Synopsis
- Mutations in the CBP/p300 histone acetyltransferase (HAT) domain are linked to leukemia and affect leukocyte compartment sizes.
- The small-molecule A485 was found to quickly mobilize leukocytes from bone marrow to blood, showing similar effectiveness as granulocyte colony-stimulating factor (G-CSF) but working through a different mechanism.
- A485 activation of the HPA axis influences leukocyte distribution via specific hormones, suggesting a potential new approach for rapidly increasing blood leukocyte levels to help treat various human diseases.
B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T cells revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM). However, data on cellular (CAR) T cell dynamics and the association with response, resistance or the occurrence of cytokine release syndrome (CRS) are limited. Therefore, we performed a comprehensive flow cytometry analysis of 27 RRMM patients treated with Idecabtagene vicleucel (Ide-cel) to assess the expansion capacity, persistence and effects on bystander cells of BCMA-targeting CAR T cells.
View Article and Find Full Text PDFImportance: Live vaccines (measles-mumps-rubella [MMR] and varicella-zoster virus [VZV]) have not been recommended after solid organ transplant due to concern for inciting vaccine strain infection in an immunocompromised host. However, the rates of measles, mumps, and varicella are rising nationally and internationally, leaving susceptible immunocompromised children at risk for life-threating conditions.
Objective: To determine the safety and immunogenicity of live vaccines in pediatric liver and kidney transplant recipients.